PMID- 37169143
OWN - NLM
STAT- MEDLINE
DCOM- 20230625
LR  - 20230625
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 952
DP  - 2023 Aug 5
TI  - Hesperidin may improve depressive symptoms by binding NLRP3 and influencing the 
      pyroptosis pathway in a rat model.
PG  - 175670
LID - S0014-2999(23)00181-4 [pii]
LID - 10.1016/j.ejphar.2023.175670 [doi]
AB  - OBJECTIVE: Major depressive disorder (MDD) is a debilitating psychiatric disorder 
      which is common and endangers human physical and mental health. Studies have 
      shown that hesperidin could improve the symptoms of depression with unclear 
      mechanisms. METHOD: In this study, hesperidin was administered to chronic 
      unpredictable mild stress (CUMS) depressed mice before behavioral test, network 
      pharmacology analysis, RNA expression microarray analysis, pathway validation and 
      molecular docking experiments. RESULTS: we found that hesperidin intervention 
      could significantly improve the depressive symptoms and downregulate the 
      expression level of pyroptosis pathway including caspase 1 (Casp1), interleukin 
      18 (IL18), interleukin-1beta (IL-1beta) and NOD-like receptor thermal protein domain 
      associated protein 3 (NLRP3). In addition, we found that hesperidin could 
      possibly bind to NLRP3. CONCLUSIONS: Our study demonstrated that hesperidin had 
      huge potential as anti-depressive neuroprotectant, and may play a role in 
      treating MDD by regulating NLRP3-mediated pyroptosis.
CI  - Copyright (c) 2023. Published by Elsevier B.V.
FAU - Cao, Hui
AU  - Cao H
AD  - Department of Psychiatry, Brain Hospital of Hunan Province, The Second People's 
      Hospital of Hunan Province, Changsha, China.
FAU - Yang, Dong
AU  - Yang D
AD  - Department of Psychiatry, Brain Hospital of Hunan Province, The Second People's 
      Hospital of Hunan Province, Changsha, China.
FAU - Nie, Kechao
AU  - Nie K
AD  - Department of Integrated Traditional Chinese & Western Internal Medicine, The 
      Second Xiangya Hospital, Central South University, Changsha, China.
FAU - Lin, Ruoheng
AU  - Lin R
AD  - Department of Psychiatry, The Second Xiangya Hospital of Central South 
      University, Changsha, China.
FAU - Peng, Luqi
AU  - Peng L
AD  - Department of Integrated Traditional Chinese and Western Medicine, Xiangya 
      Hospital, Central South University, Changsha, China.
FAU - Zhou, Xuhui
AU  - Zhou X
AD  - Department of Psychiatry, Brain Hospital of Hunan Province, The Second People's 
      Hospital of Hunan Province, Changsha, China.
FAU - Zhang, Mei
AU  - Zhang M
AD  - Department of Integrated Traditional Chinese and Western Medicine, Xiangya 
      Hospital, Central South University, Changsha, China.
FAU - Zeng, Ying
AU  - Zeng Y
AD  - Department of Integrated Traditional Chinese and Western Medicine, Xiangya 
      Hospital, Central South University, Changsha, China.
FAU - Liu, Lini
AU  - Liu L
AD  - Department of Psychiatry, Brain Hospital of Hunan Province, The Second People's 
      Hospital of Hunan Province, Changsha, China.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Integrated Traditional Chinese and Western Medicine, Xiangya 
      Hospital, Central South University, Changsha, China. Electronic address: 
      huangweidavid@csu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20230509
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - EC 3.4.22.36 (Caspase 1)
RN  - E750O06Y6O (Hesperidin)
RN  - 0 (Inflammasomes)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Rats
MH  - Caspase 1
MH  - Depression/drug therapy
MH  - *Depressive Disorder, Major
MH  - *Hesperidin/pharmacology/therapeutic use
MH  - Inflammasomes/metabolism
MH  - Molecular Docking Simulation
MH  - NLR Family, Pyrin Domain-Containing 3 Protein/metabolism
MH  - Pyroptosis
OTO - NOTNLM
OT  - Hesperidin
OT  - Major depressive disorder
OT  - NLRP3
OT  - Pyroptosis
COIS- Declaration of competing interest The authors declare no conflict of interests.
EDAT- 2023/05/12 01:07
MHDA- 2023/06/19 13:08
CRDT- 2023/05/11 19:33
PHST- 2022/09/02 00:00 [received]
PHST- 2023/03/20 00:00 [revised]
PHST- 2023/03/21 00:00 [accepted]
PHST- 2023/06/19 13:08 [medline]
PHST- 2023/05/12 01:07 [pubmed]
PHST- 2023/05/11 19:33 [entrez]
AID - S0014-2999(23)00181-4 [pii]
AID - 10.1016/j.ejphar.2023.175670 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2023 Aug 5;952:175670. doi: 10.1016/j.ejphar.2023.175670. Epub 
      2023 May 9.